Filing Flows › BioMarin Pharmaceutical (BMRN) › Capital expenditures
BioMarin Pharmaceutical (BMRN) capital expenditures by quarter
BioMarin Pharmaceutical's capital expenditures were $28.3M in Q3 2026 (third quarter 2026), -2% from Q2 2026. Over the last 7 quarters it ranged from $16.8M (Q1 2025) to $40.7M (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $28.3M | -2% | -0.5% |
| Q2 2026 | $28.8M | +38% | +69% |
| Q1 2026 | $20.9M | -49% | +25% |
| Q4 2025 | $40.7M | +43% | — |
| Q3 2025 | $28.4M | +66% | — |
| Q2 2025 | $17.1M | +2% | — |
| Q1 2025 | $16.8M | — | — |
Q3 2026 at a glance
BioMarin Pharmaceutical, Q3 2026: revenue $1.0B (+32% year over year), operating margin -8.0%, net loss $123M, operating cash flow $188M. The chart follows the revenue to costs, profit and cash.
Questions
What is BioMarin Pharmaceutical's capital expenditures?
BioMarin Pharmaceutical's capital expenditures were $28.3M in Q3 2026 (third quarter 2026), -2% from Q2 2026.
How has BioMarin Pharmaceutical's capital expenditures changed?
Over the last 7 quarters it ranged from $16.8M (Q1 2025) to $40.7M (Q4 2025).
Q3 2026 results → · How BioMarin Pharmaceutical makes money →